Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Follow The CEO? Abbott Chief Chooses Diversified Products, Emerging Markets Over Rx Drugs As Company Splits In Two

This article was originally published in PharmAsia News

Executive Summary

Abbott Laboratories CEO Miles White has complained for a long time that U.S. investors don't understand the growth opportunity of emerging markets. Now White finally has a chance to put his money where his mouth is, choosing to lead a diversified medical products company rather than an innovative pharmaceutical company that will carry a different name, following a decision to split Abbott into two companies

Related Content

Abbott To Split Into Two Publicly Traded Companies Over Next 12 Months
Abbott To Split Into Two Publicly Traded Companies Over Next 12 Months
Abbott Established Products Senior VP Michael Warmuth Stresses Diversified Portfolio In Emerging Markets: An Interview With PharmAsia News (Part 2 of 2)
Abbott Plays On Diverse Offering As It Cruises Higher Than Most In India
Pfizer: Established Products And Consumer Health In; Animal Health And Nutrition Out
Are Emerging Markets Part Of Big Pharma's Core Business?
BMS Benefits From Focused Strategy, Novartis Looks To Vaccines; Abbott Tries To Educate U.S. Investors: Emerging Markets Earnings Roundup (Part 2)
Abbott, Eli Lilly, Novartis: Emerging Markets Earnings Round Up (Part 1)
Piramal Deal Done, Abbott's India Plunge May Fetch Big Returns, But Integration Challenges, Growth Momentum Critical
Abbott Set To Launch Xience Prime Stents In India; Says Solvay's Products Will Broaden Focus



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts